These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 30425010)

  • 1. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Faria R; Soares MO; Spackman E; Ahmed HU; Brown LC; Kaplan R; Emberton M; Sculpher MJ
    Eur Urol; 2018 Jan; 73(1):23-30. PubMed ID: 28935163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.
    Patel S; Rongen JJ; Fütterer JJ; Boltyenkov A; Rovers MM
    Eur Urol Oncol; 2018 Dec; 1(6):476-483. PubMed ID: 31158091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
    Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
    Magnani CJ; Hernandez-Boussard T; Baker LC; Goldhaber-Fiebert JD; Brooks JD
    J Urol; 2022 Jul; 208(1):80-89. PubMed ID: 35212570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
    Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
    Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
    White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
    Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
    Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
    JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia.
    Gordon LG; James R; Tuffaha HW; Lowe A; Yaxley J
    J Magn Reson Imaging; 2017 May; 45(5):1304-1315. PubMed ID: 27726240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.
    Cerantola Y; Dragomir A; Tanguay S; Bladou F; Aprikian A; Kassouf W
    Urol Oncol; 2016 Mar; 34(3):119.e1-9. PubMed ID: 26602178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
    Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer.
    van der Sar ECA; Kasivisvanathan V; Brizmohun M; Freeman A; Punwani S; Hamoudi R; Emberton M
    Eur Urol Focus; 2019 Jan; 5(1):62-68. PubMed ID: 28753883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.